Dawnrays Pharmaceutical (Holdings) 2348.HK · HKD

Its shares trade on HKEX under the ticker 2348.HK. It has been listed since 11 July 2003. In the fiscal year to 31 December 2025, it reported revenue of CN¥1.43bn and net income of CN¥249.2m. At that date it held total assets of CN¥4.67bn and shareholders' equity of CN¥3.94bn.

Dawnrays Pharmaceutical Holdings Ltd. operates as an investment holding company, which engages in the development, manufacturing and selling of cephalosporin antibiotics, and various system specific medicines. The company employs 989 full-time employees The company went IPO on 2003-07-11. The products include intermediate pharmaceutical, bulk medicines and finished drugs. The firm operates its business through two segments. The Intermediates and Bulk Medicines segment is engaged in the manufacture and sale of intermediates and bulk medicines. The Finished Drugs segment is engaged in the manufacture and sale of finished drugs, including antibiotics finished drugs and non-antibiotics finished drugs.

Figures and description from our data supplier, not checked against the company's own report.

• Ms. Kei Ling LiExecutive Chairman of the Board, since 2019CN¥965,000
• Ms. Liwei YuChief Executive Officer
• Mr. Yijun WuChief Financial Officer
• Mr. Yung Lai HungExecutive Director, since 2002CN¥616,000
• Ms. Kit Ling PangCompany Secretary
• Mr. Hong Man LeungNon-Executive DirectorCN¥249,000
• Mr. Hao Xi EdeIndependent Non-Executive Director
• Ms. Ming Yee LamIndependent Non-Executive Director
• Mr. Tung Sing LoIndependent Non-Executive Director

Overall

0

Environment

0

Social

0

Governance

0

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.